CENTOGENE Announces Approval of All Resolutions Tabled at 2023 Annual General Meeting
CENTOGENE Announces Shareholder Approval of All Resolutions at 2023 Annual General Meeting
CENTOGENE Announces Shareholder Approval of All Resolutions at 2023 Annual General Meeting
CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration
CENTOGENE Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
CENTOGENE today announced financial results for the fiscal year ended December 31, 2022, and provided a business update.
CENTOGENE to Participate in Upcoming Conferences in May
CENTOGENE Receives Nasdaq Non-Compliance Notice
CENTOGENE Accelerates Global Genetic Data Interpretation, Launching FilterTool Application as Accessory to CentoCloud® Bioinformatics Pipeline
CENTOGENE to Participate in Upcoming Conferences in April
CENTOGENE Launches NEW CentoGenome, World’s Most Comprehensive Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
IQVIA and CENTOGENE have formed a collaboration to improve health outcomes for rare disease patients by accelerating and de-risking clinical development and increasing access to genetic testing.
Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the appointment of Ian Rentsch as Chief Commercial Officer and General Manager – Pharma, who will join the Company on March 15, 2023.
CENTOGENE today announced its conference schedule for March 2023.
In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD)
Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has received a notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department informing the Company that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1).
